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A B S T R A C T   
Background: : Tranexamic acid (TXA) is an antifibrinolytic drug that reduces surgical blood loss and death due to 
bleeding after trauma and post-partum haemorrhage. Treatment success is dependant on early intervention and 
rapid systemic exposure to TXA. The requirement for intravenous (IV) administration can in some situations limit 
accessibility to TXA therapy. Here we employ physiologically based pharmacokinetic modelling (PBPK) to 
evaluate if adequate TXA exposure maybe achieved when given via different routes of administration. 
Methods: : A commercially available PBPK software (GastroPlus®) was used to model published TXA pharma-
cokinetics. IV, oral and intramuscular (IM) models were developed using healthy volunteer PK data from twelve 
different single dose regimens (n = 48 participants). The model was verified using separate IV and oral validation 
datasets (n = 26 participants). Oral, IM and sub-cutaneous (SQ) dose finding simulations were performed. 
Results: : Across the different TXA regimens evaluated TXA plasma concentrations varied from 0.1 to 94.0 µg/mL. 
Estimates of the total plasma clearance of TXA ranged from 0.091 to 0.104 L/h/kg, oral bioavailability from 36 to 
67% and Tmax from 2.6 to 3.2 and 0.4 to 1.0 h following oral and intramuscular administration respectively. 
Variability in the observed TXA PK could be captured through predictable demographic effects on clearance, 
combined with intestinal permeability and stomach transit time following oral administration and muscle blood 
flow and muscle/plasma partition coefficients following intra-muscular dosing. 
Conclusions: : This study indicates that intramuscular administration is the non-intravenous route of adminis-
tration with the most potential for achieving targeted TXA exposures. Plasma levels following an IM dose of 
1000 mg TXA are predicted to exceed 15 mg/mL in < 15 min and be maintained above this level for approxi-
mately 3 h, achieving systemic exposure (AUC0–6) of 99 to 105 µg*hr/mL after a single dose. Well-designed 
clinical trials to verify these predictions and confirm the utility of intramuscular TXA are recommended.   
1. Introduction 
Acute severe bleeding is a leading cause of death (Wang et al., 2015). 
Traumatic extracranial haemorrhage, often the consequence of road 
traffic crashes or violence, is responsible for more than two million 
deaths each year (Bruns and Hauser, 2003). Traumatic intracranial 
bleeding are common causes of death and disability with an estimated 
69 million new cases each year (Dewan et al., 2018). Postpartum hae-
morrhage (PPH) is a leading cause of maternal mortality and morbidity. 
About 6% to 10% of all women giving birth develop PPH and it accounts 
for around 100,000 maternal deaths every year (Calvert et al., 2012; 
Carroli et al., 2008; World Health Organization et al., 2015). 
Ninety-nine percent of deaths from PPH are in low and middle-income 
countries (LMICs) (Say et al., 2014). Many women who survive expe-
rience severe morbidity. Some women need surgery to control the 
bleeding and many require a hysterectomy, thus removing the possi-
bility of having more children. 
Tranexamic acid (TXA) is a synthetic analogue of the amino acid 
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lysine, which inhibits fibrinolysis by blocking the lysine binding sites on 
plasminogen. TXA reduces bleeding by inhibiting the enzymatic 
breakdown of fibrin blood clots (McCormack, 2012). Plasminogen pro-
duced by the liver is converted into the fibrinolytic enzyme plasmin by 
the tissue plasminogen activator (tPA). Plasminogen and tPA bind to 
lysine residues on fibrin leading to localised plasmin formation and 
fibrin cleavage (McCormack, 2012). TXA is a molecular analogue of 
lysine that inhibits fibrinolysis by competing with fibrin for the lysine 
binding sites in plasminogen. TXA inhibits the capacity of plasminogen 
and plasmin to bind to fibrin, hence preserving blood clots from 
plasmin-mediated lysis (McCormack, 2012). 
TXA has been shown to reduce the risk of death from trauma and 
PPH. The WOMAN trial assessed the effects of intravenous TXA in 
20,060 women with PPH (Shakur et al., 2017). TXA significantly 
reduced death due to bleeding with no adverse effects. When given 
within three hours of birth, TXA reduced death due to bleeding by nearly 
one-third (relative risk (RR)=0.69, 95% CI 0.52 to 0.91; p = 0.008). 
However, for many women, treatment is too late to prevent death from 
PPH. Most PPH deaths occur in the first hours after giving birth (Shakur 
et al., 2017). In both trauma and PPH, every fifteen minutes treatment 
delay reduces the survival benefit by about 10% until around three 
hours after which there is no benefit (Gayet-Ageron et al., 2018). One of 
the main barriers to rapid treatment is the need for an intravenous (IV) 
injection. IV TXA can rapidly achieve therapeutic blood concentrations 
of >10 mg/L, the concentration above which substantial inhibition of 
fibrinolysis has been observed (Picetti et al., 2019). 
If TXA could be given intramuscularly for trauma, it could be given 
by trained first responders, police officers, ambulance drivers, and pri-
mary care nurses with important reductions in time to treatment. 
Intramuscular TXA might also increase access to treatment for women 
with postpartum haemorrhage (PPH). In low- and middle-income 
countries, about 40% of women deliver at home. Although community 
health workers are often present, most cannot give IV drugs. Transport 
to hospital can take hours, and many women exsanguinate on the way 
(Kironji et al., 2018) .Although IV TXA is the treatment of choice, this is 
not an option for tens of thousands of women. Finding alternative to IV 
TXA administration in women with PPH is a WHO research priority 
(Vogel et al., 2018). To facilitate this, developing understanding on how 
alternative routes to IV TXA administration could impact the pharma-
cokinetics (PK) is needed. 
The objective of this study was to use published literature data to 
develop a physiologically-based PK model that predicts the plasma 
concentration-time (Cp-time) profile of TXA following IV, oral (PO) and 
intra-muscular (IM) dosing. After the TXA model was defined and vali-
dated, simulations were performed to predict if appropriate systemic 
concentrations of TXA could be achieved rapidly enough by either oral, 
IM or sub-cutaneous (SQ) administration. This work builds on the meta- 
analysis carried out by Grassin-Delyle et al. (2019) 
2. Methods 
2.1. Search strategy 
Advantage was taken of the search conducted for a previously pub-
lished systematic review on the pharmacodynamics of TXA (Picetti 
et al., 2019). This search contained terms related to PK and all routes of 
administration. That search was complemented with an additional 
search until June 2018 for this work. Inclusion criteria comprised any 
studies conducted in healthy volunteers which reported the PK of TXA 
administered via the following routes: intravenous, oral (ingestion or 
sublingual), intraosseous, intra-muscular, sub-cutaneous or trans-
dermal. Two reviewers independently assessed records to determine 
whether they met the inclusion criteria. Titles and abstracts were 
screened, and the full texts of any potentially relevant reports were 
assessed for inclusion. Disagreements between reviewers were resolved 
by consensus. 
2.2. Data extraction and handling 
PK data sources and key study information are summarised in 
Table 1. TXA pharmacokinetic data was either manually transcribed or 
digitally extracted from the selected source publications using DigitTM 
version 1.0.4 (a plot digitizer tool from Simulations Plus Inc., Lancaster, 
CA, USA). Where concentration-time (Cp-time) data is reported for 3 (or 
less) subjects the individual subject data has been directly transcribed 
into GastroPlus. Where Cp-time data in more than 3 subjects is reported 
an arithmetic mean Cp-time profile has been calculated and this average 
profile used during modelling. To aid data visualization all model pre-
dictions and simulation results have been exported from the modelling 
software and summary plots have been constructed using R version 
3.4.4. 
2.3. Pharmacokinetic model development 
The modelling reported here has been performed using GastroPlus® 
(version 9.5, Simulations Plus Inc., Lancaster, CA, USA) a commercially 
available PBPK software. Where demographic data was not reported in 
the source reference, the default GastroPlus® Population Estimates for 
Age-Related (PEAR) settings have been used. Where body weight was 
not recorded default weights of 86.3, 69.1 and 61.7 kg, were assumed for 
European/American, Chinese and Japanese subjects respectively. When 
demographic information provided included age but not body weight, 
the default PEAR body weight for the observed age was used. TXA is 
known to be primarily excreted unchanged in the urine with overall 
renal clearance equalling total plasma clearance (Pilbrant et al., 1981). 
Glomerular filtration rate (GFR) as calculated by GastroPlus® is 
dependant on the ethnicity, gender, age and body weight defined in the 
PEAR physiology file. Within this TXA model, all plasma clearance is 
achieved through renal filtration (CLfilt) which has been defined as 
equal to the calculated glomerular filtration rate (GFR). The Gastro-
Plus® PEAR physiology settings used are shown in Table 2, a European 
PEAR physiology was not available, so the American settings were 
applied for European subjects. Where measured in vitro data was not 
available to inform parameter estimates for essential physical chemical 
properties, ADMET® version 7.2 (Simulations Plus Inc., Lancaster, CA, 
USA) was used to predict these properties from structure. 
See Fig. 1 for a flow chart describing the model development 
strategy. 
All tissues within the whole body PBPK model have been specified as 
permeability limited and tissue partitioning coefficients (Kp’s) were 
calculated using the Poulin and Theil extracellular method (Poulin and 
Theil, 2009, 2000). Because of the low molecular weight of TXA, para-
cellular permeability was included in the model and calculated using the 
Zhimin method (Zhimin, 1995). To allow the observed PK variability 
following oral and IM dosing to be described certain critical absorption 
parameters in the intestine and at the site of injection were fitted to the 
observed PK profiles and allowed to vary across the model development 
datasets. 
2.4. Pharmacokinetic model validation 
Intravenous and immediate release (IR) oral TXA PK profiles taken 
from a Lysteda registration study; NDA 022430 study XP12B-101, were 
used as an external model validation dataset (Xanodyne Pharmaceuti-
cals Inc., 2009). 
During model development the key sources of IV and PO PK vari-
ability were identified. To allow the external validation data set to be 
predicted ‘typical’ estimates for these key parameters were defined as 
follows: 
All subjects in study XP12B-101 (Xanodyne Pharmaceuticals Inc., 
2009) were female however no body weight or age information for the 
individual participants was available. The American female PEAR 
physiology (30 years old, 75.2 Kg) along with the core model parameters 
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(Table 3) defined the clearance and distribution of TXA enabling pre-
diction of the IV validation PK (1000 mg). 
An average effective human permeability (Peff) and fasted stomach 
transit time (STT) were calculated using the respective model develop-
ment parameters estimates, these average estimates were then used 
along with the American female PEAR physiology (30 years old, 75.2 
Kg) and core model parameters (Table 3) to predict the oral validation 
PK (1300 mg fasted state). 
2.5. Pharmacokinetic simulations 
Single dose oral, IM and SQ simulations were performed and eval-
uated against a target plasma concentration of 15 mg/L, the time to 
exceed this concentration was also considered. A simulation time of 6 h 
was employed for all administration routes. 
The default American female PEAR physiology was used in all sim-
ulations; 30 years old, 75.2 kg. 
Oral simulations were performed assuming administration of a so-
lution formulation of TXA. Since solution formulations are known to 
gastric empty more quickly than solid dosage forms a STT of 0.1 hour 
was employed in all oral simulations. 
For the other critical absorption parameters found to describe the 
observed PO and IM PK variability estimates informed by model 
development were used when performing simulations. 
3. Results 
Six publications were identified as eligible for inclusion in this study, 
providing the data used for model development (Chang et al., 2004; 
Eriksson et al., 1974; Pilbrant et al., 1981; Puigdellivol et al., 1985; 
SANO et al., 1976; Sindet-Pedersen, 1987), while data from the Lysteda 
regulatory filing; study XP12B-101, NDA 022430, was used for model 
validation (Xanodyne Pharmaceuticals Inc., 2009). All publications 
were in English, except for one in Japanese (SANO et al., 1976) that was 
translated with the help of a Japanese native speaker. In total, 12 
different TXA PK regimens were evaluated (10 used in model develop-
ment and 2 in model validation) in which 74 participants (of which 42% 
were female) received tranexamic acid (TXA), individual study de-
mographics are presented in Table 1. Across the model development 
data sets plasma concentrations ranged from 0.2 to 94.0 µg/mL, 
0.2–14.5 µg/mL and 1.3–21.1 µg/mL following IV, oral and IM dosing 
respectively. For the method validation datasets plasma concentrations 
ranged from 0.1 to 90.4 µg/mL after 1000 mg IV and from 0.1 to 12.9 
µg/mL after a 1300 mg oral dose. 
TXA (4-(Aminomethyl)cyclohexanecarboxylic acid) is a low molec-
ular weight (157.21 g/mol) zwitterionic compound and aqueous solu-
bility and plasma protein binding are reported to be 167 mg/mL in water 
(Merck Index Online, 2020), >50 mg/mL at pH 6.5–8.0 and 3% bound 
respectively (Pharmacia and Upjohn Co, 2020). Visych et al. (2016) 
reports a Caco-2 average permeation rate of 12.4 × 10–06 ± 0.1 cm/s, 
(Visych et al., 2016) however no marker data is published alongside 
thereby making the result of limited use in PBPK model development. 
The effective human permeability (Peff) predicted from structure using 
the ADMET predictor software is 0.75×10–04 cm/s. No other relevant 
measured physical-chemical information was found in the literature. 
Table 3 summarises all core (fixed across all datasets) model pa-
rameters, highlighting if parameters were measured, predicted from 
structure or fitted using the model development PK datasets. 
Using NCA of the model predicted IV Cp-time profiles evaluated in 
this study, the average total plasma clearance (CLp) and average volume 
of distribution at steady state (Vss) of TXA are estimated to be 0.10 L/h/ 
kg (range: 0.091 to 0.104 L/h/kg) and 0.59 L/kg (range: 0.546 – 0.613 
L/kg) 
Variability in the oral PK across studies was primarily captured 
through variability in permeability and stomach transit time, see 
Table 4. Estimates of Peff ranged from 0.38 to 0.50×10–4 cm/s (average 
= 0.45×10–4 cm/s) across the model development studies evaluated, 
and STT ranged from 0.38 to 0.75 h in the fasted state (average = 0.54 
h). A stomach transit time of 1.0 hour adequately described the two fed 
state datasets evaluated. However, when modelling the Pilbrant fed 
Table 1 
PK data sources and key study information.  
Source Route Fed/ 
Fasted 
Dose (mg) Duration of sampling (h) Sex/N Ethnicity  BW (kg) Age (Yrs) 
Eriksson (1974) IV na 1000 8 M/2 European 67,69 37, 29 
Pilbrant (1981) IV na 1000 32 M/3 European 66,80,73 39,43,36  
PO Fed/ 
Fasted 
2000 6 M/10 European Not reported Not reported 
Puigdellivol (1985) IV na 500 8 M/3 European Not reported 23,25,33  
IM na 500 8 M/3 European Not reported 23,25,33 
Sano (1976) IV na 1000 6 M/2 Japanese 77,75 48,51  
PO Fed 500 6 M/5 Japanese 58,67,67,54,52 24,44,37,44,48  
IM na 500 6 M/3 Japanese 77,75,65 48,51,39 
Sindet-Pedersen (1987) PO Fasted 1000 8 M/5, F/5 European 54 - 90 (□ = 70) 23 - 29 (□ = 25) 
Chang (2004) PO Fasted 500 12 12 Chinese Not reported Not reported 
Validation (XP12B-101) IV na 1000 36 F/26 American Not available Not available  
PO Fasted 1300 36 F/26 American Not available Not available 
Model development datasets: Chang et al., 2004; Eriksson et al., 1974; Pilbrant et al., 1981; Puigdellivol et al., 1985; SANO et al., 1976; Sindet-Pedersen, 1987. 
Model validation dataset: NDA 022,430 study XP12B-101, Xanodyne Pharmaceuticals Inc., 2009. 
Table 2 
PEAR physiology file settings .  









IV American 71 36 M 1.919 
Pilbrant PO American 86.27 30 M 2.005 
Puigdellivol IV, 
IM 
American 85.12 27 M 2.038 
Sano IV Japanese 76 50 M 1.763 
Sano IM Japanese 72 46 M 1.797 
Sano PO Japanese 60 39 M 1.876 
Sindet- 
Pedersen1 
PO American 70 25 M1 2.052 






American 75.22 30 F 2.005  
1 Sindet-Pederson dosed 5 M and 5F subjects but due to software constraints in 
the PEAR file all subjects specified as male.  
2 GFR (mL/s) calculated by GastroPlus based on built in regression models and 
specified weight, age and population.  
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state data, (Pilbrant et al., 1981) an increase in the default Jejunum pH 
was required (J1 compartment pH increased from 5.4 to 6.0) because of 
the significant impact that intestinal pH had on the amount of predicted 
paracellular permeability, and therefore overall fraction absorbed (Fa), 
see Fig. 2 (right panel). Using the default fed state J1 pH of 5.4 a small 
negative food effect (FE) is predicted (approx. 20% reduction in AUC 
compared to fasted state) and this was not observed by Pilbrant (Pil-
brant et al., 1981). 
Only 2 IM PK datasets were identified, and the IM specific model 
parameters used to describe the observed variability in IM PK are 
summarised in Table 5. 
Both IM datasets were simulated using the minimum calculated 
depot volume of 42.4 mL. Blood flow (Q) at the site of injection was 
found to be a very influential parameter on the predicted IM PK profile 
and the Sano (SANO et al., 1976) and Puigdellivol (Puigdellivol et al., 
1985) IM PK were best described using muscle blood flow 2–3.5 times 
lower than the default muscle blood flow (2.86 mL/min/100 g). In 
addition, while the core model parameters (pKa, Log P, PPB%, Rbp and 
specific permeability surface area product) combined with the Poulin 
and Theil extracellular tissue partition co-efficient (Kp) estimation 
Fig. 1. Tranexamic acid model development strategy. Figure key: 12-(Puigdellivol et al., 1985), 13-(Sano 1976), 14-(Chang 2004), 15-(Eriksson et al., 1974), 
16-(Pilbrant et al., 1981), 17-(Sindet-Pedersen 1987), 26-(Zhimin 1995), 27-(Poulin 2000), 28-(Poulin 2009), 29-(Pharmacia and Upjohn 2020). 
PBPK model development strategy. 
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method (Poulin and Theil, 2009, 2000) adequately describe tissue dis-
tribution for 6 out of the 7 studies evaluated this was not the case for the 
Puigdellivol dataset (Puigdellivol et al., 1985). To capture the slower IM 
absorption rate seen by Puigdellivol the muscle Kp was increased from 
the calculated value of 0.97 to 2.0, see Fig. 2 (IM; middle and IV; left 
panels). The increase in muscle Kp has only a minor impact on the 
overall Vss and shape of the predicted IV plasma profile however it does 
have a significant impact on the extracellular fraction of unbound drug 
in muscle (Fuext) which when dosing directly to the intramuscular 
compartment significantly reduces the unbound extracellular concen-
tration of TXA at the site of injection thereby slowing the rate of systemic 
absorption. 
3.1. Model performance 
TXA plasma Cp-time profiles were simulated using the relevant pa-
rameters detailed in Tables 2, 3, 4 and 5. The full, predicted Cp-time 
profiles are shown compared to the observed data for each regimen 
evaluated in Fig. 3. The relevant summary statistics (Cmax, AUC, Tmax) 
and associated prediction errors (PE) are compared in Table 6. Across 
the populations, doses and routes of administration evaluated, the 
model performed with an average PE of 9 and 6% on Cmax and AUC0-t, 
respectively (Table 6). Considering the IV and oral validation dataset, 
both the predicted Cmax and AUC0-t are within 10% of the observed 
values (Xanodyne Pharmaceuticals Inc., 2009). 
Regarding the observed Cmax in the Sano et al. study, (SANO et al., 
1976) and the high prediction error (48%), the infusion time is reported 
to be 4 min, however the first blood sample was not taken until T = 15 
min. If a 15 min infusion time is assumed when simulating the Sano data 
Table 3 
Core model parameters.  
Parameter Abbreviation Units Value Source 
pKa / Solubility 
Factor 
pKa / SF na Acid 4.51 / 
7.8 
Predicted 
from structure    
Base 10.28 / 
7.8  
Lipophilicity Log P na − 1.79 Predicted 
from structure 
Molecular Weight Mw g/mol 157.21 Predicted 
from structure 
Ref solubility at pH 7 Ref Sol mg/ 
mL 
50 Measured 1 
Blood to plasma ratio Rbp na 1 Fitted 
Plasma protein 
binding 
PPB % 3 Measured 1 






1.081×10–5 Fitted  
1 (Pharmacia and Upjon Co, 2020).  
Table 4 
Permeability and stomach transit time parameter estimates associated with oral 
PK modelling.  
Parameter Pilbrant Sindet- 
Pedersen 
Sano Chang Average Source 
Permeability x 
10–4 (cm/s) 
0.4 0.38 0.5 0.5 0.45 Fitted 
Fasted STT (h) 0.51 0.751 na 0.382 0.54 Fitted1 / 
Default2 
Fed STT (h) 1 na 1 na 1 Default 
na: not applicable. 
Fig. 2. Visualisation of i) the impact of muscle tissue partition coefficient (Kp) on the predicted concentration time profile following IM and IV dosing (left and 
middle panel) and ii) the impact of fed state jejunum (J1) pH following oral dosing (right panel). The open red circles represent the observed data from the 
Puigdellivol (ref 12) and Pilbrant (ref 16) study, the solid black and dashed lines represent predicted plasma concentration time profiles. (For interpretation of the 
references to colour in this figure legend, the reader is referred to the web version of this article.) 
Table 5 
Muscle blood flow and partition co-efficient parameter estimates associated with 
IM PK modelling.  
Parameter Sano Puigdellivol Source 
Muscle Q at SOI (mL/min/100 g 
muscle) 
0.82 1.37 Fitted 
Muscle Kp 0.971 22 Calculated1 / 
Fitted2 
Kp values are calculated based on pKa, Log P, PPB%, Rbp and specific perme-
ability surface area product. 
combined with the Poulin and Theil extracellular tissue partition co-efficient 
(Kp) estimation method. 
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Fig. 3. Model performance. Comparison of observed plasma concentrations (red open circles) with predicted levels (solid black line) for model development and 
validation datasets, see Table 1 for individual study details and Tables 2-5 for model parameters. Where appropriate and the necessary data was available, error bars 
show the standard deviation in plasma concentration at a given timepoint. (For interpretation of the references to colour in this figure legend, the reader is referred to 
the web version of this article.) 
Table 6 
Comparison of observed and predicted TXA pharmacokinetics across all datasets evaluated.  
Source Route Ethnicity Dose (mg) Pred F% Tmax (h) Cmax (µg/mL) AUC0-t (µg*h/mL) R2 
Obs Pred Obs Pred PE (%) Obs Pred PE (%)  
Eriksson, Pilbrant IV European 1000  0.08 0.08 86.8 99.8 15 126.0 129.5 3 0.97 
Puigdellivol 1 IV European 500  0.08 0.08 33.4 25.7 − 23 41.9 51.5 23 0.63 
Sano 2 IV Japanese 1000  0.26 0.07 59.8 88.6 48 104.0 111.9 8 0.78 
Validation IV American 1000  0.05 0.08 90.4 95.2 5 120.7 126.1 4 0.83 
Pilbrant (fed) PO European 2000 36 3.00 3.24 14.5 13.2 − 9 61.3 58.2 − 5 0.91 
Pilbrant (fasted) PO European 2000 38 3.00 2.74 13.9 14.3 3 59.5 63.1 6 0.95 
Sindet (fasted) PO European 1000 36 3.00 2.85 6.6 7.0 6 33.9 36.3 7 0.97 
Sano (fed) PO Japanese 500 54 2.00 3.14 6.0 6.0 0 25.0 25.9 0.04 0.91 
Chang (fasted) PO Chinese 500 67 2.53 2.64 7.8 7.5 − 4 42.7 41.5 − 3 0.98 
Validation PO American 1300 52 3.07 2.64 12.9 12.2 − 5 77.8 76.2 − 2 1.00 
Sano IM Japanese 500 99 0.50 0.44 21.1 20.4 − 3 58.6 56.0 − 4 0.97 
Puigdellivol IM European 500 99 0.83 0.99 12.3 13.3 8 45.3 50.7 12 0.92 
Average         4   4   
1 Administration was a bolus IV injection, therefore peak concentrations have been compared at the time of the first observation.  
2 Infusion time and time of first plasma observation are inconsistent, predicted Tmax and Cmax reflects the source stated infusion time (4 mins).  
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the predicted Cmax is reduced to 59.8 µg/mL (0% Cmax PE). 
3.2. PO Simulations 
Two simulated oral Cp-time profiles (PO Sim1 and PO Sim2) are 
presented in Fig. 4 (top left panel), both assume dosing of 4000 mg as a 
solution (40 mL of a 100 mg/mL) administered in the fasted state. A 
stomach transit time of 0.1 h was used in both simulations, while PO 
Sim1 assumes a Peff of 0.4 × 10–4 cm/s and PO Sim2 a Peff of 0.5 ×
10–4 cm/s. The permeability estimates used reflect (to 1.d.p) the highest 
and lowest values required to simulate the observed oral PK (Table 4 and 
Fig. 3) and for comparison the average Peff value of 0.45×10–4 cm/s 
was used when simulating the oral validation dataset (Xanodyne Phar-
maceuticals Inc., 2009). The default human fasted advanced compart-
mental absorption and transit model (ACAT) was used and all other 
model parameters were as defined in Table 3 and Section 2.5. 
The first oral simulation (PO Sim1; Peff = 0.4 × 10–4 cm/s) resulted 
in a Cmax of 33 µg/mL, AUC0-t 143 µg*h/mL and Tmax 2.1 h. The 
second simulation (PO Sim2; Peff = 0.5 × 10–4 cm/s) resulted in a Cmax 
of 45 µg/mL, AUC0-t 190 µg*h/mL and Tmax 2.0 h. 
3.3. IM Simulations 
IM Cp-time profiles were simulated for a solution dose of 1000 mg. 
The site of injection was defined as the gluteus. Due to software limi-
tations, only a single 10 mL injection volume (of 100 mg/mL solution) 
could be simulated, rather than two 5 mL injections as would be 
clinically recommended, (Hopkins and Arias, 2013) thus resulting in a 
larger depot volume. In these simulations, the minimum calculated 
depot volume of 84.7 mL was employed. 
Table 7 summarises for the four IM simulations (IM Sim1-IM Sim4) 
the estimates used for Q and Kp at the site of injection (gluteus muscle). 
These ranged from the default values for Q (2.86 mL/min/100 g muscle) 
and Kp (0.97) to a three fold lower estimate of Q (0.95 mL/min/100 g 
muscle) and 2 fold higher estimate of Kp (1.94), values informed by the 
Fig. 4. Simulation results. Different line types illustrate the predicted impact of; intestinal permeability (oral) and tissue blood flow and tissue partition coefficients 
(IM and SQ). For these key parameters, a range of estimates informed by model development were used in the simulations. See Table 7 and Section 3.2. for the 
corresponding simulation parameters. Top left - oral single dose 4000 mg fasted state. Top right - intramuscular single dose 1000 mg. Bottom left - sub-cutaneous 
single dose 1000 mg. Bottom right - sub-cutaneous single dose 2000 mg. 
Table 7 
























IM1 2.86 0.97 84.7 1000 60 105 0.1 
IM2 2.86 1.94   38 102 0.5 
IM3 0.95 0.97   44 105 0.4 
IM4 0.95 1.94   28 99 1.1 
SQ1 2.6 0.97 74 1000 31 102 1.0 
SQ2 2.6 1.94   21 90 1.7 
SQ3 0.87 0.97   20 88 1.9 
SQ4 0.87 1.94   12 62 3.1 
SQ5 2.6 0.97 74 2000 63 205 1.0 
SQ6 2.6 1.94   42 181 1.7 
SQ7 0.87 0.97   40 176 1.9 
SQ8 0.87 1.94   25 123 3.1  
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model development work, see Table 5. 
The resulting predicted IM PK parameters (Cmax and AUC) are also 
presented in Table 7. The simulated Cp-time profiles (IM1-IM4) are 
presented in Fig. 4 (top right panel) and show that even then slowest 
absorption rate (IM Sim4) plasma levels are predicted to exceed 15 µg/ 
mL in ≤ 15 min. Concentrations are predicted to be maintained above 
the target level for between 2.5–3 h. Bioavailability via the IM route is 
predicted to be 100%, but the practical dose volume limitations mean 
the overall predicted AUC0-t (99 µg*h/mL) is 2.6 fold lower than the 
best case 4000 mg oral prediction; simulation PO2. 
3.4. SQ Simulations 
SQ Cp-time profiles were simulated for doses of 1000 mg initially but 
increased to 2000 mg in order to exceed the 15 µg/mL target concen-
tration. In GastroPlus® the dose volume for a SQ administration is 
capped at 10 mL so for the 2000 mg simulation it was necessary to as-
sume a 200 mg/mL solution of TXA was dosed, the feasibility of this 
concentration, from a formulation perspective, is unknown. The site of 
injection (SOI) was defined as adipose in the leg and as with IM dosing 
the same software limitations regarding the use of multiple injection 
sites applied. Therefore the minimum calculated depot volume of 74 mL 
was used in all SQ simulations. 
Human PK data following SQ administration of TXA has never pre-
viously been published, therefore the same strategy developed for the IM 
simulations was employed; default software estimates and three fold 
lower for adipose blood flow (2.6 and 0.87 mL/min/100 g adipose) and 
default software estimates and 2 fold higher for adipose Kp (0.97 and 
1.94). Table 7 summarises the adipose blood flow at the site of injection 
and adipose Kp used in each SQ simulation and the resulting predicted 
PK parameters (Cmax, AUC and Tmax). The simulated Cp-time profiles 
are presented in Fig. 4 (bottom panels). 
4. Discussion 
The present study describes the development of a PBPK model that 
can accurately describe single dose IV, oral (fasted and fed) and intra- 
muscular administrations of TXA (Chang et al., 2004; Eriksson et al., 
1974; Pilbrant et al., 1981; Puigdellivol et al., 1985; SANO et al., 1976; 
Sindet-Pedersen, 1987). PK data from six different single dose studies 
performed in healthy volunteers were utilised during model develop-
ment. External validation of the model was performed for the IV and PO 
routes of administration and prediction errors on Cmax and AUC0-t were 
≤ 10% for both routes (Xanodyne Pharmaceuticals Inc., 2009). Across 
study variability in PK was captured through demographic (ethnicity, 
gender, age and body weight) effects on GFR, Vss and key absorption 
parameters specific to the route of administration. Intestinal perme-
ability and stomach transit time were significant factors following oral 
dosing and muscle blood flow and partition coefficient were significant 
following IM dosing. 
The range of values estimated by this model for total plasma clear-
ance are compatible with TXA clearance values reported elsewhere in 
healthy volunteers and in cardiac surgery patients (Grassin-Delyle et al., 
2013; Nilsson, 1980; Pharmacia and Upjohn Co, 2020; Pilbrant et al., 
1981; Sharma et al., 2012). 
No measured data was available on the blood to plasma ratio (Rbp) 
for TXA. Based on structure a Rbp of 1.35 was predicted using the 
ADMET software (version 7.2), however the data sets upon which these 
predictions are based are significantly smaller than for critical physical 
chemical properties such as Log P and pKa and higher variability in 
biological measures, such as Rbp, mean these predictions are not typi-
cally as accurate. The predicted value was tested during method 
development but a value of 1.0 better captured the observed volume of 
distribution. 
A potential limitation of this work may result from the reduced 
number of participants involved in some of the source PK studies and a 
lack of associated demographic information. In addition no published 
PK data following SQ administration of TXA was found and therefore SQ 
simulations were performed by applying the same strategies as devel-
oped during modelling of observed IM PK data. 
Other potential limitations include the fact that, apart from in the 
Sindet-Pederson study where 50% of the participants were female, 
(Sindet-Pedersen, 1987) all the participants in the model development 
studies were male, while the model validation study only included fe-
male subjects (Xanodyne Pharmaceuticals Inc., 2009). However for the 
validation dataset the predicted Cmax and AUC0-t were within 10% of 
the observed values, which does suggest that gender does not play a 
significant role in the PK of TXA. 
Finally, despite an extensive search for all eligible PK data it is 
possible that some relevant studies may have been missed. 
It is of note that using the Puigdellivol et al. data, the prediction error 
calculated for the IV AUC0-t was high, with the model over predicting 
the observed AUC0-t by 23%. This may be due to an under prediction of 
renal filtration in these participants which may be confounded by a lack 
of body weight information. The IV plasma levels reported by Puigdel-
livol et al. do stand out as lower and more variable than the other IV PK 
datasets evaluated during this work, however subject numbers in the 
Puigdellivol study were limited (n = 3) making it difficult to draw 
conclusions (Puigdellivol et al., 1985). 
TXA is a high solubility compound, the oral bioavailability of which 
is limited by intestinal permeability. Oral bioavailability has been pre-
dicted to vary from 36 to 67% across the datasets evaluated and due to 
the absence of any significant first pass extraction in the liver or gut, oral 
bioavailability directly represents the fraction of drug absorbed (Fa). 
The oral bioavailability of the TXA regimens evaluated Pilbrant et al. 
were reported to be 33 and 34%, with our model predicting 36 and 38% 
respectively. Due to the low permeability of TXA even small differences 
in the effective human permeability (Peff) have been shown to have a 
significant effect on Fa . Whilst the high solubility of TXA means we 
would not expect formulation effects to limit the extent of exposure, 
certain formulation factors may influence the rate of absorption and 
while the European studies (Pilbrant et al., 1981; Sindet-Pedersen, 
1987) used the same oral drug product (multiple 500 mg Cyklokapron 
tablets), the oral formulations used by Chang et al. and Sano et al. are 
unclear, as are the specific formulation details of the IR reference tablet 
dosed in the study XP12B-101 (Xanodyne Pharmaceuticals Inc., 2009). 
After PO administration, plasma TXA concentrations are predicted to 
exceed 15 µg/mL within 15–30 min, to peak at between 30 and 60 µg/ 
mL in 2 h and be maintained above 15 µg/mL for 5–6 h. The oral sim-
ulations presented here assumed rapid (0.1 h) gastric emptying of a 
solution formulation which is considered to be a reasonable assumption. 
Slower gastric emptying would result in slower absorption. 
Comparitively there is more uncertainty associated with our IM 
predictions due to less data available for model development, significant 
variability in the two available datasets and the absence of an external 
validation dataset. Therefore, a larger number of parameter scenarios 
were evaluated (IM Sim1 to IM Sim4). All however predict that plasma 
concentrations exceed 15 µg/mL in ≤ 15 min when a 1000 mg dose is 
administered. Peak concentrations following a 1000 mg IM dose are 
comparable to the 4000 mg oral predictions, 30–60 µg/mL. The IM 
Tmax however is more ambiguous and a range of 0.1 to 1 h was pre-
dicted, with plasma levels falling below 15 µg/mL in 2.5 to 3.5 h. Muscle 
blood flow was identified as a very sensitive parameter during model 
development, and clinically is expected to be an important consideration 
as blood flow varies in different skeletal muscles (Evans et al., 1975; 
Vučićević et al., 2015). 
Very little is known about the SQ use of TXA. Whilst there are reports 
of this route of administration being used for dermatological surgeries 
(Sagiv et al., 2018; Zilinsky et al., 2019) pharmacokinetic studies after 
SQ injection of TXA are not available. Based on our simulations SQ 
administration of TXA appears to be the route with the lowest potential 
for success using currently available formulation options. If a 2000 mg 
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dose could be achieved through use of a higher concentration TXA so-
lution SQ administration may become a more viable option. However, 
time to peak concentrations are still only either comparable to those 
predicted via the oral route, or slower with the most conservative pa-
rameters estimates (Table 7 and Fig. 3, simulations SC4 and SC8). 
5. Conclusions 
This analysis suggests further clinical evaluation of TXA adminis-
tered via intra-muscular injection is warranted as it is predicted to be a 
valid alternative to IV administration for fast delivery of a therapeutic 
dose of TXA to the blood. High doses of TXA administered orally as a 
solution may also provide a valid administration method. However, 
studies including larger sample sizes are required to better describe the 
pharmacokinetics of alternative, but less characterized routes of 
administration of TXA, both in healthy volunteers and in emergency 
settings to account for traumatic situations such as hypovolemia. 
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